Von Willebrand disease (vWD) is an inherited trait where an individual’s bleeds excessively. It is very rare that it is acquired late in life due to autoantibodies due to the impairment of protein called von Willebrand factor, important component in blood–clotting process. The vWF gene is located on chromosome 12. Types 1 and 2 are inherited as autosomal dominant traits and type 3 is inherited as autosomal recessive. VWF is especially the bleeding from mucous membranes.
Disease statistics: As per the research data depicts that the prevalence of severe von Wille-brand's disease is influenced by ethnic and geographic factors. As per the research conducted it has been observed that the 1185A/G von Willebrand factor gene polymorphism and coronary artery disease.
Treatment: The two main treatment possibilities for patients with von Willebrand disease (vWD) are desmopressin (DDAVP) and von Willebrand factor/factor VIII (vWF/FVIII) concentrates. DDAVP is a synthetic analogue of the antidiuretic hormone vasopressin; it has enhanced antidiuretic activity and no pressor activity related to vasopressin. Purified plasma-derived concentrates of vWF/FVIII are used for treatment of bleeds and for surgical prophylaxis when DDAVP is ineffective or contraindicated.
Research: The correct diagnosis and classification of Von Willebrand disease (VWD) is important for therapy and genetic counseling but is made difficult due to the variability of its clinical expression and limitations of laboratory methods.